Novartis: data shows psoriasis drug is superior

(CercleFinance.com) - New data reinforces the superiority of Cosentyx versus Janssen's Stelara in achieving skin clearance for psoriasis patients, Novartis said on Tuesday.


A 12-week trial showed that 66.5% and 72.3% of patients treated with Novartis' human inhibitor achieved both co-primary endpoints, compared to 47.9% and 55.4% patients, respectively, treated with Stelara.

Cosentyx is already approved in 80 countries for the treatment of moderate-to-severe plaque psoriasis.

Also note that Sandoz, Novartis' generics division, said that the FDA has accepted its biologics license application for proposed biosimilar adalimumab to reference medicine, AbbVie's Humira.

The drug can be used for the treatment of a number of inflammatory diseases, including rheumatoid arthritis, plaque psoriasis, Crohn's disease and ulcerative colitis.

Copyright (c) 2018 CercleFinance.com. All rights reserved.